$PALI

Jones Mitchell Lawrence sold $107K of PALI

Jones Mitchell Lawrence (Chief Medical Officer) sold 51,880 shares of PALISADE BIO, INC. (PALI) at $2.05 ($0.11M total) on 2026-07-07.

Original reporting
SEC EDGAR · Jones Mitchell Lawrence
Published Jul 8, 2026, 10:52 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 8, 2026, 10:55 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PALI
Neutral
high confidence
Mentioned
$PALI
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PALINeutralLow
01

Why it matters

The newest concrete fact is the CMO’s open-market sale of 51,880 shares at $2.0535, with holdings after the trade of 94,009 shares and no 10b5-1 plan indicated.

02

Market read

Traders may note insider selling, but the filing provides no fundamental update (no trial, guidance, or deal) to drive a decisive repricing.

03

What to watch

The text does not state whether the insider’s remaining holdings are subject to other plans, nor does it provide context on prior sales frequency or compensation structure.

Relevance 4/10Novelty 3/10Timing: Filed 2026-07-08 after-hours; reflects sale executed 2026-07-07.

Background

The article is a SEC Form 4 insider transaction disclosure for Palisade Bio, Inc.

Company-level read

Ticker impact

$PALINeutralHigh confidence
Context

Form 4 shows Chief Medical Officer Jones Mitchell Lawrence sold 51,880 shares of Palisade Bio at $2.0535 on 2026-07-07.

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale.

Evidence & confidence

The filing is an insider sale (not a buy), the disclosed transaction size is modest, and there is no accompanying corporate event, guidance, or regulatory action in the text.

Market effects

No sector read-across provided; this is company-specific insider activity only.

None indicated.

None indicated.

Counterpoint

Insider sales can be tax or diversification-driven and may not reflect negative company outlook, especially without any other adverse disclosures.

Key entities

  • Palisade Bio, Inc.

    Company whose Form 4 insider sale is disclosed.

  • Jones Mitchell Lawrence

    Chief Medical Officer who sold shares via open-market sale.

Related articles